1.Inhibition of Janus activated kinase-3 protects against myocardial ischemia and reperfusion injury in mice.
Young Bin OH ; Min AHN ; Sang Myeong LEE ; Hyoung Won KOH ; Sun Hwa LEE ; Suhn Hee KIM ; Byung Hyun PARK
Experimental & Molecular Medicine 2013;45(5):e23-
Recent studies have documented that Janus-activated kinase (JAK)-signal transducer and activator of transcription (STAT) pathway can modulate the apoptotic program in a myocardial ischemia/reperfusion (I/R) model. To date, however, limited studies have examined the role of JAK3 on myocardial I/R injury. Here, we investigated the potential effects of pharmacological JAK3 inhibition with JANEX-1 in a myocardial I/R model. Mice were subjected to 45 min of ischemia followed by varying periods of reperfusion. JANEX-1 was injected 1 h before ischemia by intraperitoneal injection. Treatment with JANEX-1 significantly decreased plasma creatine kinase and lactate dehydrogenase activities, reduced infarct size, reversed I/R-induced functional deterioration of the myocardium and reduced myocardial apoptosis. Histological analysis revealed an increase in neutrophil and macrophage infiltration within the infarcted area, which was markedly reduced by JANEX-1 treatment. In parallel, in in vitro studies where neutrophils and macrophages were treated with JANEX-1 or isolated from JAK3 knockout mice, there was an impairment in the migration potential toward interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1), respectively. Of note, however, JANEX-1 did not affect the expression of IL-8 and MCP-1 in the myocardium. The pharmacological inhibition of JAK3 might represent an effective approach to reduce inflammation-mediated apoptotic damage initiated by myocardial I/R injury.
Animals
;
Apoptosis/drug effects
;
Cell Movement/drug effects
;
Chemokines/pharmacology
;
Heart Function Tests/drug effects
;
Inflammation/pathology
;
Janus Kinase 3/*antagonists & inhibitors/metabolism
;
Macrophages/drug effects/metabolism/pathology
;
Male
;
Mice
;
Mice, Inbred C57BL
;
Myocardial Reperfusion Injury/drug therapy/*enzymology/physiopathology/*prevention & control
;
Myocardium/enzymology/pathology
;
Myocytes, Cardiac/drug effects/metabolism/pathology
;
Neutrophils/drug effects/metabolism/pathology
;
Quinazolines/pharmacology/therapeutic use
2.Pretreatment with Tongxinluo protects porcine myocardium from ischaemia/reperfusion injury through a nitric oxide related mechanism.
Yu-tong CHENG ; Yue-jin YANG ; Hai-tao ZHANG ; Hai-yan QIAN ; Jing-lin ZHAO ; Xian-min MENG ; Fu-liang LUO ; Yi-ling WU
Chinese Medical Journal 2009;122(13):1529-1538
BACKGROUNDThe traditional Chinese medicine Tongxinluo can protect myocardium against ischaemia/reperfusion injury, but the mechanism of its action is not well documented. We examined the involvement of nitric oxide in the protective role of Tongxinluo.
METHODSMiniswine were randomized to four groups of seven: sham, control, Tongxinluo and Tongxinluo coadministration with a nitric oxide synthase inhibitor N(omega)-nitro-L-arginine (L-NNA, 10 mg/kg i.v.). Three hours after administration of Tongxinluo, the animals were anaesthetised and the left anterior descending coronary artery ligated and maintained in situ for 90 minutes followed by 3 hours of reperfusion before death. Area of no reflow and necrosis and risk region were determined pathologically by planimetry. The degree of neutrophil accumulation in myocardium was obtained by measuring myeloperoxidase activity and histological analysis. Myocardial endothelial nitric oxide synthase activity and vascular endothelial cadherin content were measured by colorimetric method and immunoblotting analysis respectively.
RESULTSTongxinluo significantly increased the local blood flow and limited the infarct and size of no reflow. Tongxinluo also attenuated myeloperoxidase activity and neutrophil accumulation in histological sections and maintained the level of vascular endothelial cadherin and endothelial nitric oxide synthase activity in the reflow region when compared with control group. The protection of Tongxinluo was counteracted by coadministration with L-NNA.
CONCLUSIONSTongxinluo may limit myocardial ischaemia and protect the heart against reperfusion injury. Tongxinluo regulates synthesis of nitric oxide by altering activity of endothelial nitric oxide synthase.
Animals ; Antigens, CD ; analysis ; Blood Pressure ; drug effects ; Cadherins ; analysis ; Drugs, Chinese Herbal ; therapeutic use ; Heart Rate ; drug effects ; Microscopy, Fluorescence ; Myocardial Infarction ; drug therapy ; physiopathology ; Myocardial Reperfusion Injury ; prevention & control ; Myocardium ; enzymology ; pathology ; Neutrophil Infiltration ; Nitric Oxide ; physiology ; Nitric Oxide Synthase ; metabolism ; Peroxidase ; metabolism ; Swine ; Swine, Miniature